SCHEMBL25760291

SCHEMBL25760291

Cc1cccc(-c2cn3c(=O)c(Cc4cccs4)nc-3c(Cc3ccccc3)[nH]2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.36
▸ MEN1 O00255 4/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ PTGS2 P35354 1/20 0.35
▸ ADORA2A P29274 1/20 0.35
▸ ADORA2B P29275 1/20 0.35
▸ ADORA1 P30542 1/20 0.35
▸ MAPT P10636 4/20 0.34
▸ KDM4E B2RXH2 3/20 0.34
▸ HPGD P15428 3/20 0.34
▸ NPSR1 Q6W5P4 3/20 0.34
▸ THRB P10828 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2681471 0.91 KDM4E (0.38) KMT2AMEN1RAB9ASMN1; SMN2NPC1
SCHEMBL25760294 0.90 RAB9A (0.40) KMT2AMEN1RAB9ASMN1; SMN2NPC1
SCHEMBL21751286 0.89 PIK3CA (0.38) KMT2AMEN1SMN1; SMN2PTGS2ADORA2A
SCHEMBL21751391 0.86 MAOA (0.33) KMT2AMEN1SMN1; SMN2ADORA2AADORA2B
SCHEMBL30800183 0.86 MAOA (0.33) KMT2AMEN1SMN1; SMN2ADORA2AADORA2B
SCHEMBL25760166 0.85 THRB (0.38) KMT2AMEN1RAB9ASMN1; SMN2NPC1
SCHEMBL20543611 0.85 THRB (0.42) KMT2AMEN1RAB9ASMN1; SMN2NPC1
SCHEMBL5555425 0.84 KDM4E (0.35) RAB9ASMN1; SMN2L3MBTL1PTGS2ADORA2A
SCHEMBL25760289 0.84 KMT2A (0.36) KMT2AMEN1RAB9ASMN1; SMN2NPC1
SCHEMBL25760270 0.84 ADORA2B (0.38) KMT2AMEN1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691976-B2 Coelenterazine analogues PROMEGA CORPORATION (US) 2023-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691976-B2 Coelenterazine analogues GLB1, SI, TCF7L2 KMT2A 2122/4885MEN1 1826/4885RAB9A 1793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback